Schrutka Lore, Distelmaier Klaus, Hohensinner Philipp, Sulzgruber Patrick, Lang Irene M, Maurer Gerald, Wojta Johann, Hülsmann Martin, Niessner Alexander, Koller Lorenz
Division of Cardiology, Department of Internal Medicine II, Medical University of Vienna, Austria.
Ludwig Boltzmann Cluster for Cardiovascular Research, Vienna, Austria.
J Am Heart Assoc. 2016 Dec 21;5(12):e004169. doi: 10.1161/JAHA.116.004169.
Oxidative stress is mechanistically linked to the pathogenesis of chronic heart failure (CHF). Antioxidative functions of high-density lipoprotein (HDL) particles have been found impaired in patients with ischemic cardiomyopathy; however, the impact of antioxidative HDL capacities on clinical outcome in CHF patients is unknown. We therefore investigated the predictive value of antioxidative HDL function on mortality in a representative cohort of patients with CHF.
We prospectively enrolled 320 consecutive patients admitted to our outpatient department for heart failure and determined antioxidative HDL function using the HDL oxidative index (HOI). During a median follow-up time of 2.8 (IQR: 1.8-4.9) years, 88 (27.5%) patients reached the combined cardiovascular endpoint defined as the combination of death due to cardiovascular events and heart transplantation. An HOI ≥1 was significantly associated with survival free of cardiovascular events in Cox regression analysis with a hazard ratio (HR) of 2.28 (95% CI 1.48-3.51, P<0.001). This association remained significant after comprehensive multivariable adjustment for potential confounders with an adjusted HR of 1.83 (95% CI 1.1-2.92, P=0.012). Determination of HOI significantly enhanced risk prediction beyond that achievable with N-terminal pro-B-type natriuretic peptide indicated by improvements in net reclassification index (32.4%, P=0.009) and integrated discrimination improvement (1.4%, P=0.04).
Impaired antioxidative HDL function represents a strong and independent predictor of mortality in patients with CHF. Implementation of HOI leads to a substantial improvement of risk prediction in patients with CHF.
氧化应激在机制上与慢性心力衰竭(CHF)的发病机制相关。已发现缺血性心肌病患者高密度脂蛋白(HDL)颗粒的抗氧化功能受损;然而,抗氧化HDL能力对CHF患者临床结局的影响尚不清楚。因此,我们在一组具有代表性的CHF患者队列中研究了抗氧化HDL功能对死亡率的预测价值。
我们前瞻性纳入了320例连续入住我院门诊治疗心力衰竭的患者,并使用HDL氧化指数(HOI)测定抗氧化HDL功能。在中位随访时间2.8(四分位间距:1.8 - 4.9)年期间,88例(27.5%)患者达到了综合心血管终点,该终点定义为心血管事件导致的死亡和心脏移植的组合。在Cox回归分析中,HOI≥1与无心血管事件生存显著相关,风险比(HR)为2.28(95%置信区间1.48 - 3.51,P<0.001)。在对潜在混杂因素进行全面多变量调整后,这种关联仍然显著,调整后的HR为1.83(95%置信区间1.1 - 2.92,P = 0.012)。HOI的测定显著增强了风险预测能力,超过了N末端B型利钠肽原所能达到的预测能力,净重新分类指数(32.4%,P = 0.009)和综合判别改善(1.4%,P = 0.04)表明了这一点。
抗氧化HDL功能受损是CHF患者死亡率的一个强有力的独立预测因素。HOI的应用显著改善了CHF患者的风险预测。